Clinic
University of Texas Health Science Center at Tyler
University of Texas Health Science Center at Tyler was paid $2.00M by Medicaid between Apr 2019 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoUNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER
TYLER, TX 75708
TYLER, TX 75708
33aNPI1417941295assigned 09/07/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$2.00M
24GClaims74,678
24DCodes billed100
24AFirst – last monthApr 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#116 of 320
Median peer was paid$205K
This provider vs. median9.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 167 | $1K | |
| 2020 | 802 | $34K | |
| 2021 | 16,723 | $286K | |
| 2022 | 25,269 | $792K | |
| 2023 | 20,699 | $666K | |
| 2024incomplete | 11,018 | $218K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 947 | 886 | $306K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12% | 12,689 | 11,223 | $236K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 419 | 376 | $205K |
| 94010 | 10% | 1,325 | 1,273 | $200K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 2,468 | 2,386 | $175K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.3% | 703 | 677 | $87K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.1% | 1,101 | 1,065 | $81K |
| 71046 | Radiologic examination, chest; 2 views | 3.8% | 1,002 | 963 | $77K |
| 80053 | Comprehensive metabolic panel | 3.2% | 8,522 | 7,469 | $64K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 740 | 645 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 9,888 | 8,107 | $51K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 849 | 821 | $48K |
88 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.4% | 206 | $48K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.9% | 642 | $38K |
| 90791 | Psychiatric diagnostic evaluation | 1.8% | 250 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 619 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 184 | $24K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 207 | $21K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 77 | $20K |
| 94664 | <1% | 290 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,910 | $18K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 166 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,934 | $12K |
| 80061 | Lipid panel | <1% | 1,311 | $10K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 78 | $9K |
| 82728 | <1% | 1,387 | $8K | |
| 80050 | General health panel | <1% | 37 | $6K |
| 70360 | <1% | 91 | $6K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 19 | $6K |
| 87428 | <1% | 136 | $6K | |
| 83540 | <1% | 1,199 | $6K | |
| 94060 | <1% | 19 | $5K | |
| 95012 | <1% | 225 | $5K | |
| 84466 | <1% | 912 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 135 | $5K |
| 83615 | <1% | 1,208 | $3K | |
| 97162 | <1% | 14 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 56 | $3K |
| 84439 | <1% | 442 | $3K | |
| 90686 | <1% | 131 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 110 | $2K |
| 81001 | <1% | 973 | $2K | |
| 82948 | <1% | 473 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 206 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 73 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 73 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 64 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,197 | $2K |
| 85610 | <1% | 378 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,259 | $1K |
| 82607 | <1% | 144 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 38 | $900.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 139 | $824.55 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $821.28 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 44 | $768.74 |
| 87430 | <1% | 27 | $701.44 | |
| 99490 | Ccm add 20min | <1% | 314 | $611.07 |
| 84703 | <1% | 70 | $587.92 | |
| 80076 | <1% | 44 | $573.42 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 97 | $547.81 |
| 81003 | <1% | 376 | $526.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 359 | $516.58 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $500.30 |
| 0071A | <1% | 13 | $487.80 | |
| 82043 | <1% | 113 | $448.09 | |
| 85027 | <1% | 41 | $432.12 | |
| 86780 | <1% | 37 | $366.96 | |
| 82565 | <1% | 43 | $351.99 | |
| 82570 | <1% | 80 | $327.87 | |
| 90661 | <1% | 17 | $322.80 | |
| 87070 | <1% | 26 | $258.90 | |
| 80143 | <1% | 12 | $241.42 | |
| 82378 | <1% | 31 | $240.88 | |
| 86803 | <1% | 71 | $237.16 | |
| 80179 | <1% | 12 | $225.76 | |
| 84484 | <1% | 26 | $212.42 | |
| 88142 | <1% | 12 | $204.24 | |
| J2704 | Injection, propofol, 10 mg | <1% | 205 | $156.51 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 231 | $128.35 |
| 0002A | <1% | 12 | $120.00 | |
| 0003A | <1% | 81 | $120.00 | |
| 83550 | <1% | 26 | $105.48 | |
| 85652 | <1% | 25 | $83.43 | |
| 83735 | <1% | 26 | $70.44 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 90 | $67.43 |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,478 | $57.25 |
| 87210 | <1% | 12 | $53.79 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16 | $22.34 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 517 | $21.29 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 39 | $0.00 |
| 90662 | 0% | 12 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 15 | $0.00 |
| 36416 | 0% | 117 | $0.00 | |
| 91307 | 0% | 47 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 96 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 14 | $0.00 |
| A9270 | Non-covered item or service | 0% | 23 | $0.00 |
| 83880 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKAVASCH, KRIS (VP FINANCE/CFO)
| Provider | Location | Paid |
|---|---|---|
| University of Texas Health Science Center at Tyler-Facility-Physician | Tyler, TX | $1.93M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.